BIOVECTRA, a part of Agilent Technologies Inc., and Revolution Biomanufacturing Inc. today announced a collaboration that grants BIOVECTRA access to Revolution Biomanufacturing's proprietary platforms ...

The manufacture and release of mRNA therapeutics and vaccines is a complex and challenging process requiring a high degree of expertise, capabilities, and experience. The development and manufacturing ...

LineaRx will present its Linea™ IVT platform - a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase (Linea™ RNAP) - as a ...

In this free webinar, gain insight into how mRNA performance can be strengthened through sequence design and GMP-aligned development strategies. Attendees will learn how codon optimization and UTR ...

The emerging field of mRNA therapeutics is still young. This class of therapeutics is poised to have broad implications in the treatment of many indications in addition to infectious diseases such as ...

— Partnership Combines Sequence Design Expertise with End-to-End GMP Manufacturing to Streamline mRNA Development and Scale-up — BIOVECTRA, a part of Agilent Technologies Inc., and Revolution ...

STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced its participation at upcoming mRNA ...

- Co-Hosts Seminar with mRNA CDMO Kudo Bio to Demonstrate Linea IVT Capability for Rapid mRNA Manufacturing - STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc.